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In the colon, long-term exposure to chronic inflammation drives colitis-associated colon
cancer (CAC) in patients with inflammatory bowel disease. While the causal and clinical links
are well established, molecular understanding of how chronic inflammation leads to the
development of colon cancer is lacking. Here we deconstruct the evolving microenvironment
of CAC by measuring proteomic changes and extracellular matrix (ECM) organization over
time in a mouse model of CAC. We detect early changes in ECM structure and composition,
and report a crucial role for the transcriptional regulator heat shock factor 1 (HSF1) in
orchestrating these events. Loss of HSF1 abrogates ECM assembly by colon fibroblasts in cell-
culture, prevents inflammation-induced ECM remodeling in mice and inhibits progression to
CAC. Establishing relevance to human disease, we find high activation of stromal HSF1
in CAC patients, and detect the HSF1-dependent proteomic ECM signature in human
colorectal cancer. Thus, HSF1-dependent ECM remodeling plays a crucial role in mediating
inflammation-driven colon cancer.
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Colorectal cancer (CRC) is one of the leading causes ofcancer-related deaths, world-wide. CRC is usually causedby a combination of genetic and environmental factors,
leading to dysplastic lesions and eventually carcinoma. A parti-
cularly aggressive subtype of CRC is colitis-associated colon
cancer (CAC), arising in patients with inflammatory bowel dis-
ease (IBD) due to long-term exposure to chronic inflammation1.
Different than the adenoma-dysplasia-cancer progression of
sporadic CRC, CAC develops from an accumulation of somatic
mutations that mediate progression from inflamed mucosa to
dysplasia to carcinoma2,3. The spectrum of genomic alterations in
CAC is distinct from that of sporadic CRC—alterations in TP53,
IDH1, and MYC are significantly more frequent in CAC, and
mutations in APC are significantly less frequent, than those
reported in sporadic CRC2. Both the initiation and the progres-
sion of CAC are expedited by the inflammatory insult4,5. Such
inflammatory signals are mediated through dynamic crosstalk
between cancer cells and cells of the tumor microenvironment
(TME). The TME comprises various types of non-malignant
stromal cells, including macrophages, neutrophils, lymphocytes,
endothelial cells, and cancer-associated fibroblasts (CAFs).
Fibroblasts are major constituents of the normal colon, where
they are mostly quiescent and function to maintain ECM integrity
and limit epithelial cell proliferation and differentiation6. Fibro-
blasts provide fibers and connector proteins that give structure to
tissue, and produce specialized ECMs by expressing and secreting
a variable repertoire of structural proteins7. In severely injured or
chronically inflamed tissues, fibroblasts produce excessive ECM,
which, without reciprocally balanced degradation, results in
fibrosis and can eventually lead to cancer7–9. Co-evolving with
the cancer cells, fibroblasts in tumors are recruited and rewired to
become protumorigenic CAFs that support critical aspects of
malignancy by secretion of cytokines, chemokines, and growth
factors10. CAFs secrete distinct matrix components and remo-
deling enzymes from those secreted by normal fibroblasts,
resulting in aberrant ECM composition and topography which
contribute to increased stiffness of the tumor11 and promote
tumor invasion and progression12. Moreover, proteases secreted
by CAFs cleave and activate growth factors, cytokines, and cell
adhesion molecules (CAMs) embedded in the ECM, increasing
cancer cell motility and EMT6. Unlike cancer cells, CAFs are
genomically stable, and do not harbor oncogenic mutations that
could drive their co-evolution and functional reprogramming.
Instead, stromal reprogramming is achieved by massive tran-
scriptional rewiring13–18.
Heat shock factor 1 (HSF1), master regulator of the heat-shock
response, enables the transcriptional rewiring of fibroblasts into
protumorigenic CAFs13. HSF1 has historically been studied in the
context of thermal stress. A key role in cancer was established
when Hsf1 null mice were found to be extremely resistant to
tumorigenesis19. This phenomenon was initially attributed
mainly to HSF1’s activity in cancer cells19,20; however, a com-
plementary crucial role for HSF1 was recently demonstrated in
CAFs13,21. The stromal HSF1 program is completely different
from the program HSF1 drives in the adjacent cancer cells13,20 or
during heat-shock. In fibroblasts co-cultured with cancer cells
HSF1 drives the expression of genes involved in adhesion and
wound healing, leading to activation of genes involved in ECM
organization in adjacent cancer cells13,21. This is a fundamental
survival mechanism that appears to have been subverted to
support the growing tumor in a non-cell-autonomous manner.
As a pro-survival factor, HSF1 was previously shown to play a
protective role in acute colitis in mice22. When exposed to one
course of dextran sulfate sodium (DSS) treatment (7 days), Hsf1
null mice displayed a more severe form of colitis compared to
their wild-type (WT) counterparts. The effect of HSF1 was
mediated through heat shock protein (HSP)70, and involved
suppression of proinflammatory cytokines and CAMs22. In
colitis-induced cancer, however, HSF1’s protective activity was
recently shown to promote cancer23. Chronic exposure to DSS in
a model of azoxymethane (AOM)–DSS colitis-induced cancer led
to HSF1-dependent activation of mTOR and increased glutami-
nolysis in cancer cells, and promoted tumor growth.
In this work, we ask whether the protumorigenic role of HSF1
in colitis-induced cancer includes non-cell-autonomous effects on
the TME. We find that HSF1 is activated in stromal fibroblasts
during early stages of inflammation, and its activation leads to
ECM remodeling, supporting the development of colon cancer.
Using the AOM–DSS model we analyze the ECM at different
time points and find that both the structure and the composition
of the ECM change long before tumors are observed. These
inflammation-induced changes are HSF1-dependent, as is the
consequent progression to CAC. In patients, we find high acti-
vation of stromal HSF1 in CAC, and high conservation of the
HSF1-dependent proteomic ECM signature in human CRC,
confirming the relevance of our findings to human disease and
highlighting the crucial role of stromal HSF1 in CAC.
Results
Loss of HSF1 abrogates ECM secretion by fibroblasts. In a
variety of human carcinomas, HSF1 is activated in CAFs. When
co-cultured with cancer cells, fibroblasts express an HSF1-
dependent transcriptional program, which includes genes
involved in wound-healing and ECM remodeling13. To directly
assess the effect of stromal HSF1 on cancer-dependent ECM
assembly, we compared the ability of WT and Hsf1 null mouse
embryonic fibroblasts (MEFs) to deposit fibrillar collagen24,
in vitro, in the presence of conditioned media from two different
cancer cell-lines, using second harmonic generation (SHG). Loss
of Hsf1 in MEFs impeded ECM deposition induced by MC38
colon cancer-conditioned media (Fig. 1a, b) and 4T1 breast
cancer-conditioned media (Fig. 1c, d and Supplementary Fig. 1).
The surface area covered by secreted collagen was reduced in Hsf1
null MEFs compared to WT counterparts (Fig. 1a–d), suggesting
that stromal HSF1 is required for proper ECM assembly by
cancer-conditioned fibroblasts.
Loss of HSF1 attenuates inflammation-induced colon cancer.
To test whether HSF1-dependent ECM remodeling promotes
cancer in vivo, we exposed WT and Hsf1 null mice to an
inflammation-driven colon cancer model25. In this model, mice
are injected with a carcinogen, AOM, followed by two cycles of
treatment with an inflammation-inducing irritant, DSS (1.5%,
5 days), and sacrificed at day 52 post AOM injection (Fig. 2a).
Both WT and Hsf1 null mice experienced transient weight loss
following each course of DSS, with no significant differences
between the two genotypes (Fig. 2b). A similar effect was
observed following acute DSS treatment (without AOM; one cycle
of 1.5% DSS, 7 days; Supplementary Fig. 2a, b). Nevertheless,
assessment of the disease activity index (DAI; see the “Methods”
section) indicated that WT mice were sicker than Hsf1 null mice
(Fig. 2c, Supplementary Fig. 2c, Supplementary Table 1). The
DAI of WT mice increased significantly more than that of Hsf1
null mice following each cycle of DSS in the AOM-DSS protocol
(day 11–20 and day 32–52, Fig. 2c), and the WT mice did not
recover from the second cycle of DSS. While a similar trend was
observed in response to acute DSS treatment, this trend was not
significant (Supplementary Fig. 2c).
To better assess these effects we performed colonoscopy on the
AOM-DSS treated mice at day 52, and then sacrificed the mice
and examined their colons. Colonoscopy and post-mortem
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macroscopic examination of the colons revealed significant
differences between WT and Hsf1 null genotypes: not only was
tumor burden significantly lower in Hsf1 null mice compared to
WT (Fig. 2d, e, Supplementary Table 1), but Hsf1 null mice also
exhibited significantly reduced inflammation at this time point
(Fig. 2f, g, Supplementary Table 1), suggesting that the observed
effect of HSF1 on tumor burden may be mediated through
stromal effects on inflammation.
Loss of HSF1 attenuates fibrosis. Inflammation is well known to
lead to fibrosis. To test whether HSF1 affects fibrosis in the AOM-
DSS model, we examined collagen deposition at day 52 by
Masson trichrome and Sirius red staining. Both stains revealed
increased collagen-rich fibrotic regions in WT colons compared
to colons from Hsf1 null mice, suggesting that the ECM is affected
by this treatment in an HSF1-dependent manner (Fig. 3a). To
better assess these effects, we performed SHG imaging of the
affected colon crypts, as well as normal crypts from sham-treated
mice (Fig. 3b). While the structure and amount of fibrillar col-
lagen secreted in colon crypts from sham-treated animals was
similar between WT and Hsf1 null mice (Supplementary Fig. 3),
we observed stark differences between the ECM of AOM-DSS-
treated WT vs. Hsf1 null mice (Fig. 3b–l): WT mice treated with
AOM-DSS exhibited extensive fibrosis and increased thickening
of the inter-crypt walls, leading to reduction in the number of
colon crypts (Fig. 3c), increase in the size of the crypts (Fig. 3e),
and increase in the distance between crypts (Fig. 3g, h, j, k) as
compared to Hsf1 null mice, which exhibited normal ECM
morphology. The distorted ECM characteristics significantly
correlated with tumor burden, as mice with higher tumor burden
had fewer and larger crypts (Fig. 3d, f), with increased distance
between crypts (Fig. 3i, l) than mice with lower tumor burden.
HSF1-dependent inflammation-induced ECM remodeling
precedes tumor formation. The aberrant ECM morphology
found following the AOM-DSS treatment could be a result of the
heavy tumor burden on the tissue. Alternatively, HSF1-dependent
fibrosis and ECM remodeling could be driving the transition from
inflammation to cancer, in which case we would expect changes
in the ECM to precede the appearance of tumors. To investigate
this, we sacrificed AOM-DSS-treated mice at two earlier time
points, following one cycle of DSS—15 and 20 days post AOM
injection (Supplementary Fig. 4a). Acute colitis symptoms usually
peak at day 15 and decrease at day 20, as observed by the tran-
sient and concomitant changes in body weight and DAI (Sup-
plementary Fig. 4b, c). Importantly, tumors were not observed by
macroscopic or histopathological evaluation at these timepoints
(Supplementary Fig. 4d and Supplementary Table 1). Never-
theless, colonoscopy examination revealed significant inflamma-
tion in WT mice at day 20, but not in Hsf1 null mice (Fig. 4a),
suggesting that HSF1 is required for the early inflammatory
response that leads to cancer.
Histopathological examination of colon tissue revealed that even
in this early, pre-malignant stage, WT mice exhibit significantly
more inflammation and crypt damage than Hsf1 null mice (Fig. 4b,
c and Supplementary Table 1). Sirius red and Masson trichrome
staining confirmed that colons from WT mice treated with
AOM–DSS exhibited more collagen-rich fibrotic regions than
colons from Hsf1 null mice (Fig. 4d, e). SHG imaging of the colon
crypts showed that the ECM of WT mice at day 20 was highly











































Fig. 1 Loss of HSF1 impedes fibrillar collagen deposition by fibroblasts. WT or Hsf1 null immortalized MEFs were induced to secrete ECM by 7 days
incubation with conditioned media from MC38 colon cancer cells a, b or 4T1 breast cancer cells c, d supplemented by growth factors and insulin.
Representative images are shown in a, c. The average area covered by collagen in n= 4 biological independent cells, examined over four independent
experiments, each with three technical replicates, is quantified in b, d. Scale bar—50 µm. Results are shown as mean ± SEM. P value was calculated using a
two-sided unpaired Student’s t-test.
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Fig. 2 Hsf1 null mice are highly resistant to inflammation-induced cancer. a Schematic representation of the experimental protocol. WT and Hsf1 null mice
(n= 8 per group, combined from two independent experiments) were injected intraperitoneally with AOM (10mg/kg), followed by 2 × 5-day cycles of
1.5% DSS in the drinking water. b The changes in body weight of the mice throughout the experiment, and c assessment of the disease activity index (DAI)
are plotted and presented as mean ± SEM, analyzed by two-way ANOVA (with discrete time point and genotype as the independent variables) utilizing
Tukey’s test to account for multiple comparisons. d, e Tumor burden calculation based on macroscopic measures of tumors at day 52 of the AOM-DSS
protocol. Representative images of two WT (left) and two Hsf1 null (right) mouse colons are shown in e. Scale bar—1 cm. f, g Prior to sacrificing the mice at
day 52 of the AOM-DSS protocol, colonoscopies were performed and inflammation was scored as described in the “Methods” section. Representative
images from 2WT and 2 Hsf1 null mice are shown in f. Colonoscopy scores are shown in g. Results for d, g are shown as mean ± SEM, p value was analyzed
using a two-sided Welch’s test for d and by a nonparametric Mann–Whitney test for g.
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distorted, while colons from Hsf1 null mice had a normal
appearance, comparable to that of control mice (Fig. 4f–j and
Supplementary Fig. 3b–e). Colon crypts of WT mice were larger,
fewer, and more distant apart thanHsf1 null colon crypts (Fig. 4g–j).
Examination of Hsf1 null mice at the earlier timepoint of 15 days
revealed that they did in fact exhibit some ECM rearrangements
(Fig. 4f), accompanied by a slight reduction in crypt number
(compared to day 20, Fig. 4g and Supplementary Fig. 3b), and
increase in crypt damage (Supplementary Table 1) however these
changes were not significant and were resolved by day 20.
Immune profiling of colons from day 15 treated WT mice
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(CD45+CD11b+Ly6G+), macrophages (CD45+CD11b+Ly6G−
F4/80+), and monocytes (CD45+CD11b+Ly6G−F4/80−Ly6C+)
in the epithelial fraction (EF), as compared to colons from sham-
treated mice (Supplementary Fig. 4e–h). Hsf1 null mice showed
an intermediate phenotype: the above-mentioned cell populations
were somewhat increased compared to sham-treated colons,
however the differences were not statistically significant. The
increase in myeloid immune cells was transient, both in WT and
in Hsf1 null mice, as these populations returned to control levels
at day 20 of AOM–DSS treatment (Supplementary Fig. 4i–k).
These results suggest that HSF1-induced ECM remodeling
precedes tumor formation, and is required for inflammation-
driven colon cancer. They further suggest that HSF1 is not
required for initiation of acute inflammation, yet it is required for
the ensuing response to chronic inflammation.
Supporting this notion, histopathological examination of
colons from mice treated with the acute DSS protocol (DSS only,
without AOM; 8 days post treatment) revealed a modest and
similar rise in the inflammation score of WT and Hsf1 null mice
(Supplementary Fig. 5a, b and Supplementary Table 1). SHG
imaging also showed moderate and non-significant changes in
crypt number, size, and distance that were comparable between
WT and Hsf1 null mice (Supplementary Fig. 5c–i).
Taken together, these experiments suggest that an acute and
transient inflammatory signal leads to minor and transient
changes to the ECM which are HSF1-independent.
Together with an oncogenic driver, and in the context of
chronic inflammation, HSF1 is activated, leading to massive
ECM remodeling and, consequently, inflammation-driven colon
cancer.
Loss of Hsf1 affects ECM protein composition. To better
understand the mechanism by which HSF1 affects ECM remo-
deling, we performed mass spectrometry analysis of colons from
WT and Hsf1 null mice at the pre-malignant stage (day 20)
compared to control mice (day 0). We also analyzed colons at
the late, malignant stage (day 52; see the “Methods” section for
details). 3830 proteins were detected in samples from days 0–20,
and 4234 proteins were detected at day 52 (Supplementary
Data 1). Of these, only 11 proteins were differentially expressed
between WT and Hsf1 null mice at day 0 (Fig. 5a and Supple-
mentary Data 2). 20 days of treatment with AOM-DSS led to
massive changes in protein expression in WT colons, and to a
lesser extent in Hsf1 null colons (Fig. 5b and Supplementary
Data 3). At this pre-malignant stage, 42 proteins were differ-
entially upregulated in WT compared to Hsf1 null colons and 18
were downregulated (Fig. 5a and Supplementary Data 2).
Approximately a third of these differentially expressed proteins
were also differentially expressed at day 52, where a total of
136 proteins were upregulated and 178 were downregulated in
WT compared to Hsf1 null colons (Fig. 5a and Supplementary
Data 2).
To define potential pathways affected by HSF1 in our model we
performed pathway analysis on the top differentially expressed
proteins (Fig. 5b, Supplementary Fig. 6a, and Supplementary
Data 3; see the “Methods” section). Following 20 days of AOM-
DSS treatment, the most significantly upregulated proteins in WT
compared to Hsf1 null colons were ECM proteins (FN1,
LAMA1), proteins involved in inflammation, wound healing,
and innate immune responses (NFκB2, LCN2, S100A8), and
proteins involved in complement and coagulation (C3, TF;
Fig. 5b; Cluster 6, and Supplementary Data 4). Proteins involved
in oxidation–reduction responses and metabolic pathways
(ACAD10, ALDH1B1) were downregulated in 20-day treated
colons, and more so in WT colons compared to Hsf1 null colons
(Fig. 5b; Clusters 2 and 5, and Supplementary Data 4). Most of
the differentially expressed proteins exhibited a similar trend of
expression at day 52 of the AOM-DSS treatment (Supplementary
Fig. 6b, c and Supplementary Data 4).
Since HSF1 is a transcriptional regulator, we performed RNA-
sequencing of colons from the pre-malignant stage to assess
whether the observed changes to the proteome are reflected in the
transcriptome. Changes to the transcriptome are expected to
precede changes to the proteome, and therefore we collected colons
from day 15 AOM–DSS-treated mice, and compared their RNA
expression profile to that of mice from day 0 (Supplementary
Data 5). Hierarchical clustering highlighted 3506 differentially
expressed genes between day 0 and day 15 WT and Hsf1 null mice
(Supplementary Fig. 6e and Supplementary Data 6). The most
differentially upregulated genes in AOM–DSS-treated WT mice
compared to Hsf1 null mice were ECM constituents (Col18a1,
Fbln1, Lama1, Bgn), genes involved in cytokine binding (Csf1R,
Il1r1, Tgfbr2), and genes involved in inflammatory responses
(S100a8, Lcn2, Cxcl12; Cluster 3, Supplementary Fig. 6e and
Supplementary Data 7). Genes involved in oxidation–reduction and
metabolic pathways (Acad12, Aldh2, Cox7a1) were most differen-
tially downregulated in 15 day-treated WT mice, compared to Hsf1
null mice (Cluster 1, Supplementary Fig. 6e and Supplementary
Data 7). Together with the proteomic changes described above,
these findings support the notion that HSF1 drives the expression of
genes involved in ECM remodeling and inflammatory responses,
leading to the proteomic changes observed at day 20.
To further dissect the changes in ECM-associated proteins we
focused on matrisome proteins using the ECM protein expression
database MatrisomeDB26,27. This database contains ~1000 core
matrisome and matrisome-associated proteins, 107 of which were
previously identified in the normal murine colon28. 188
matrisome proteins were detected in our mass-spec analysis of
day 0–20, 82 of which overlapped with the colon matrisome
(Fig. 5c and Supplementary Data 8). 193 matrisome proteins were
Fig. 3 Hsf1 null mice exhibit reduced ECM rearrangements in colon cancer. a Representative H&E, Sirius red (SR), and Masson’s trichrome (MT) staining
of colons from WT (upper panels) and Hsf1 null (lower panels) mice following 52 days treatment with AOM-DSS (right panels) or control (sham injection
and water; left panels). Scale bar—100 µm; M—mucosa; SM—submucosa; TM—tunica muscularis; C—cancer; S—stroma. b–l Representative cross-
sections of the colons with second harmonic generation (SHG) images taken from the mucosal side b and analysis c–l of fibrillar collagen of mouse colons
following 52 days of AOM-DSS treatment or control. Scale bar—100 µm. c–f Quantification of the average crypt number c and size e, and Pearson
correlation (two-sided) between tumor burden and crypt number d and size. g–h Analysis of the average distance to the nearest crypt, within 40 µm,
calculated based on SHG images of fibrillar collagen of mouse colons following 52 days of AOM-DSS treatment or control. Representative distance
heatmaps of the SHG images presented in b are shown in g. i Pearson correlation between the average distance to the nearest crypt and tumor burden.
j–k Analysis of the number of neighboring crypts within 20 µm, calculated based on SHG images of fibrillar collagen of mouse colons following 52 days of
AOM-DSS treatment or control. Representative distance heatmaps of the SHG images presented in b are shown in k. #NN—number of nearest neighbors.
l Pearson correlation between the number of neighboring crypts and tumor burden. n= 8 mice combined from two independent experiments (one outlier
was removed in e, see the “Methods” section for details). c, e, h, k results are shown as mean ± SEM, h p value was analyzed using two-sided Welch’s
t-test, e, h, and k were analyzed by an unpaired Student’s t-test.
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-020-20054-x
6 NATURE COMMUNICATIONS |         (2020) 11:6245 | https://doi.org/10.1038/s41467-020-20054-x | www.nature.com/naturecommunications
detected at day 52, 80 of which overlapped with the colon
matrisome (Fig. 5c and Supplementary Data 8). These numbers
suggest that we detected the majority of known colon matrisome
proteins (~75%), as well as many matrix proteins which have not
been previously associated with the mouse colon. Next, we asked
which of these matrix proteins is differentially expressed in our
mass spectrometry dataset. We found 39 core matrisome and
matrisome-associated proteins differentially expressed between
control and 20-day treated WT and Hsf1 null colons (Fig. 5d, e).
Of these, 17 were previously identified as part of the murine colon
matrisome, and 22 proteins, including ECM regulators (such as
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S100A8 and S100A9), were not (Supplementary Data 8). 19 core
matrisome and matrisome-associated proteins were differentially
expressed between WT and Hsf1 null colons at day 52 of the
AOM-DSS treatment, only 10 of which were previously identified
as part of the murine colon matrisome (Fig. 5d and Supplemen-
tary Fig. 5d).
Gene expression analysis of our RNA-seq dataset revealed 234
core matrisome and matrisome-associated genes differentially
expressed between colons from day 0 and day 15 WT and Hsf1
null mice, the majority of which were upregulated in day 15 WT
mice compared to all other groups (Supplementary Fig. 6f and
Supplementary Data 9). Gene products of 41 of these were
previously identified as part of the murine colon matrisome
(Supplementary Data 9).
The fact that ~75% of the known colon matrisome was
detected in our proteomic analysis (Fig. 5c), and yet ~50% of the
differentially expressed proteins in our analysis were not
previously identified in the colon matrisome (Fig. 5d), suggests
that these proteins are specifically upregulated in inflammation
and cancer and not in the normal colon. Moreover, these findings
highlight HSF1 as a major regulator of the matrisome in
inflammation-induced colon cancer.
MMPs are upregulated and co-expressed with HSF1 in
inflamed stromal cells. Since mass-spec analysis takes a crude
average of all cells and ECM in the colon, we next validated our
mass-spec results by multiplexed immunofluorescent (MxIF)
staining with antibodies targeting HSF1 and a selected list of
potential targets. We chose for this follow-up analysis the core
matrix protein FN128, the matrix remodeling enzymes MMP729
and MMP930, the collagen-specific chaperone SERPINH131 (also
known as HSP47), and the neutrophil-associated proteins
LCN232 and S100A833,34.
To achieve a comprehensive understanding of the dynamic
changes that occur during inflammation and tumor progression
we stained colon sections from day 0, 15, 20, and 52 of the AOM-
DSS protocol, and scored expression levels and colocalization of
selected targets (see the “Methods” section for details). αSMA was
used as a marker of activated fibroblasts35 (Fig. 6a). We also
scored HSF1 nuclear expression as a proxy for its activation13,36,
and found that its expression in the stroma (Supplementary
Fig. 7a), but not in the epithelial cells of the crypt (Supplementary
Fig. 7b), reflected the disease activity (Fig. 2c) measured at the
different timepoints.
At day 0, HSF1 was scarcely detected in the stroma. At day
15 of AOM-DSS—the day at which inflammation peaks and
massive stromal infiltration is observed—HSF1 was strongly
activated, mostly in αSMA-positive fibroblasts (Fig. 6a and
Supplementary Fig. 7c, d). Similar to the DAI, activation of
stromal HSF1 subsided at day 20 and increased again at day 52
(Supplementary Fig. 7a). Epithelial HSF1 showed a different
pattern of activation—it was active in normal epithelial cells of
the crypts at day 0, its activity gradually declined in the
inflamed crypts at days 15 and 20, and increased again at
day 52, in the transformed epithelial cells of the tumors
(Supplementary Fig. 7b).
MMP7, MMP9, and LCN2 all showed HSF1-dependent
upregulation in the stroma in response to the AOM-DSS
treatment (Fig. 6a, d). While these proteins were expressed to
some extent also in the colon crypts, there was no clear trend
suggesting inflammation-dependent or HSF1-dependent expres-
sion in epithelial cells of the crypts (Supplementary Fig. 7f–h).
Next we asked whether these potential HSF1 targets are co-
expressed with HSF1 in stromal cells. Indeed, we found that
MMP7 and MMP9 partially overlapped with stromal HSF1
(Fig. 6e–g). LCN2 did not overlap with HSF1 however it did
overlap with MMP9, most likely in neutrophils (Fig. 6a and
Supplementary Fig. 6i).
S100A8, which together with S100A9 forms the calprotectin
heterocomplex, serves as a biomarker for IBD33,34. Immunostain-
ing shows that S100A8 is significantly upregulated in WT but not
in Hsf1 null colons at day 20 of the AOM-DSS protocol
(Supplementary Fig. 7j, k).
FN1 and SERPINH1 were expressed in normal colons, yet their
expression pattern changed dramatically in response to inflam-
mation in WT, but not in Hsf1 null colons (Supplementary Fig. 7l,
m). In normal colons, FN1 was expressed mostly in the walls of
the colon crypts and in the muscle, and SERPINH1 was expressed
in goblet cells. Inflammation-induced massive expression of both
of these proteins in the infiltrating stroma of WT mice but not
Hsf1 null mice (Supplementary Fig. 7l, m). Notably, the genes
encoding for FN1, SERPINH1, and MMP9 were previously
shown to be direct transcriptional targets of HSF120,37–39. Taken
together these findings suggest that inflammation induces the
activation of HSF1 in stromal fibroblasts, leading to ECM
remodeling through activation of ECM proteins, such as FN1,
matrix remodeling enzymes such as MMP7 and MMP9,
supporting chaperones such as the collagen chaperone SER-
PINH1, and immune regulatory proteins such as LCN2 and
S100A8. Some of these proteins are activated in a cell-
autonomous manner (MMP7 and MMP9), while others are most
likely activated by non-cell-autonomous signaling in neighboring
and recruited immune cells. These events lead to remodeling of
the ECM and, consequently, promote tumor progression.
Loss of Hsf1 impairs ECM deposition by colon fibroblasts,
in vitro. Our initial in vitro findings in MEFs (Fig. 1), together
with our MxIF analysis of HSF1 localization and activation in the
colon (Fig. 6), strongly indicate that, while HSF1 in cancer cells is
important for tumor growth, and HSF1 in immune cells may
contribute as well (Supplementary Fig. 4e–h), HSF1 in fibroblasts
is a major player in driving the ECM rearrangements observed in
Fig. 4 HSF1-dependent ECM remodeling precedes tumor growth. WT and Hsf1 null mice were injected intraperitoneally with AOM (10mg/kg), followed
by 5 days of 1.5% DSS in the drinking water, and sacrificed 3 or 8 days later (day 15 and 20, respectively). Age matched non-treated mice were used as
control and sacrificed at day 0. a Prior to sacrificing the mice at day 20 of the AOM-DSS protocol, colonoscopies were performed and inflammation was
scored, presented as mean ± SEM and analyzed by a nonparametric Mann–Whitney test (two-sided). b, c Colon sections were fixed, stained with H&E and
inflammation was scored by a pathologist. Representative H&E images are shown in c. M—mucosa; SM—submucosa; TM—tunica muscularis. d, e Sirius
red (SR; d) and Masson’s trichrome (MT; e) staining of colons from WT (upper panels) and Hsf1 null (lower panels) mice following 15 and 20 days
treatment with AOM-DSS (right panels) or control (left panel). Scale bar—100 µm. f Representative second harmonic generation (SHG) images of fibrillar
collagen of mouse colons following 15 and 20 days of AOM-DSS treatment or control. Scale bar—100 µm. g–j Quantification of the average crypt number
g; crypt size h; distance to the nearest crypt (within 40 µm) i; and number of neighboring crypts (within 20 µm) j in mouse colons following 15 and 20 days
of AOM-DSS treatment based on SHG signal. b, g–j results presented as mean ± SEM, analyzed by two-way ANOVA and Bonferroni correction for multiple
comparisons. n= 5 mice for both genotypes at day 15, examined over two independent experiments; n= 11 WT mice and n= 6 Hsf1 null mice for day 20
AOM-DSS treated mice, n= 2 mice for both genotypes for control; combined from two independent experiments.
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Fig. 5 Mass spectrometry analysis reveals HSF1-dependent upregulation of proteins involved in inflammation and ECM remodeling in response to
AOM-DSS. Colons from non-treated (day 0) mice, or from mice treated with AOM-DSS for 20 or 52 days were analyzed by LC–MS/MS. a Venn-diagrams
representing overlap between differentially expressed proteins upregulated (upper panel) and downregulated (lower panel) in WT vs. Hsf1 null colons at
different time points of the AOM-DSS treatment. b Heatmap of standardized mass spectrometry values of differentially expressed (DE) proteins (FC > 1.5;
FDR < 0.1) between day 0 and day 20 WT and Hsf1 null colons, clustered using K-means partition clustering into six clusters. Pathway analysis was
performed using gProfiler and selected significant pathways are shown. See also Supplementary Data 3, 4. c, d Venn-diagrams representing overlap
between the mouse colon matrisome and the matrisome proteins detected c and DE d in our mass spectrometry analysis. e Heatmap of standardized mass
spectrometry values of DE matrisome proteins (FC > 1.5; FDR < 0.1) between day 0 and day 20 WT and Hsf1 null colons, clustered by affiliation to core
matrisome and matrisome-associated groups.
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AOM-DSS-treated mice. To test this, we isolated colon fibroblasts
fromWT and Hsf1 null mice at day 15 of the AOM-DSS protocol,
allowed them to deposit fibrillar collagen, in vitro, in the presence
of MC38-conditioned media (see the “Methods” section) and
measured collagen-deposition using SHG. Similar to MEFs, 15-
day-treated WT colon fibroblasts deposited significantly more
collagen than fibroblasts from treated Hsf1 null mice (Fig. 7a, b).
We further confirmed these findings using a quantitative Sirius
red staining protocol. In this assay, colon fibroblasts isolated from
15-day treated WT or Hsf1 null mice were cultured for 5 days in
the presence or absence of MC38-conditioned media, and the
amount of fibrillar collagen produced by the cells was quantified
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by Sirius red. Cells grown in control conditions (i.e. without
growth factor-enriched MC38-conditioned media; see the
“Methods” section) produced very little fibrillar collagen,
regardless of the genotype. Upon induction with MC38-
conditioned media, WT fibroblasts produced significantly more
collagen than Hsf1 null fibroblasts (Fig. 7c). WT fibroblasts also
expressed and secreted more FN1, MMP7, and MMP9 than Hsf1
null fibroblasts (Fig. 7d–f), supporting our in vivo observations
(Fig. 6 and Supplementary Fig. 7). Cell-induced gel contraction by
WT colon fibroblasts was similar to that of Hsf1 null colon
fibroblasts (Supplementary Fig. 8a), suggesting that HSF1 does
not play an essential role in contractility. To demonstrate that
ECM deposition by colon fibroblasts is HSF1-dependent, we
used the synthetic small molecule CMLD011866 ((-)-aglaroxin
C40–42, Fig. 7g). This compound is a pyrimidinone variant of
the rocaglate/flavagline natural product class, which also
includes molecules such as rocaglamide A (RocA), a natural
product translation-initiation inhibitor previously shown to
inhibit HSF1’s activity43. CMLD011866 itself has also been
shown to inhibit the HSF1-dependent heat shock response with
an IC50 of 15.3 nM40. Treatment of WT colon fibroblasts with
CMLD011866 did not affect their viability (Fig. 7h; lower
panels). It did however significantly inhibit their ability to
deposit ECM, in vitro, as measured by SHG (Fig. 7h, i), sup-
porting the conclusion that HSF1 plays a key role in ECM
deposition by fibroblasts.
Next we set to assess the role of HSF1-dependent matrix
remodeling in supporting cancer cell proliferation. To that end we
decellularized colons from WT and Hsf1 null mice44,45, so that
only the matrix remained intact and all cells were lysed and
removed (Supplementary Fig. 8b). We then added MC38 cancer
cells and allowed them to re-cellularize the matrices for 40 h. SHG
imaging of the ECM combined with IF imaging of the cells
showed that MC38 cells re-cellularized 15-day AOM-DSS WT-
derived colons much more efficiently than they did Hsf1 null
colons from 15-day treated mice (Fig. 7j, k). A higher number of
cancer cells was found and they penetrated deeper into the matrix
of WT colons versus Hsf1 null colons (Fig. 7j; lower panels).
Cancer cells actively remodeled the matrix as apparent by “holes”
in matrix of 20-day AOM-DSS-treated WT mice but not in Hsf1
null matrix from the same time point (Fig. 7l).
These in vitro studies support the hypothesis that AOM-DSS
induces HSF1 activation in fibroblasts, leading to formation of a
pro-tumorigenic ECM that promotes cancer growth.
HSF1 is activated in human CAC. To examine the relevance of
our findings to human cancer, we performed immunohisto-
chemical (IHC) staining of human CAC patient samples with
antibodies for HSF1. To assess inflammation and fibrosis we also
performed H&E, Masson’s trichrome, and Sirius red staining of
the same samples (Fig. 8a). Notably, all of these patients exhibited
extensive fibrosis, as observed by Masson’s trichrome and Sirius
red staining. Indeed, we observed high nuclear HSF1 staining in
both cancer cells and fibroblasts in these patients compared to
control, suggesting that HSF1 is activated in human CAC
(Fig. 8a). Next, we asked whether the matrisome proteins high-
lighted by our mass-spec analysis may play a role in human colon
cancer. To answer this question, we mined the human colon
matrisome (see the “Methods” section and ref. 46). We found that
127 out of 170 matrisome proteins detected in day 0–20, and 127
out of 179 matrisome proteins detected in day 52 were previously
identified in the human colon matrisome (Fig. 8b and Supple-
mentary Data 8). Furthermore, 70% of the matrisome proteins
differentially expressed in our mass-spec analysis were identified
in the human colon matrisome (Fig. 8c and Supplementary
Data 8). Since the human colon matrisome contains data both
from normal and from CRC tissue, we next asked whether pro-
teins differentially expressed in our mouse model are upregulated
in cancer. Indeed, the matrisome proteins differentially expressed
in our mouse model were significantly enriched in proteins
upregulated in human cancer (Fig. 8d, e). The expression of many
of these proteins, including S100A8 and FN1, was higher in
cancer compared to normal human colon, and 7 were not
detected at all in the normal colon and were expressed only in
CRC (Fig. 8d, e). We further compared our list of differentially
expressed matrisome proteins to a recently published list of
matrix proteins associated with disease severity in human ovarian
cancer, and shown to be conserved in other human cancers47. 12
out of 60 proteins in the ovarian cancer list were differentially
expressed in our matrisome list (Supplementary Data 10). Of
these overlapping proteins, all of those positively correlated with
disease severity were higher in WT vs. Hsf1 null, and those
negatively correlated with disease severity were higher in Hsf1
null colons, supporting the conclusion that HSF1 positively reg-
ulates the expression of matrisome proteins contributing to ECM
remodeling in cancer. Taken together these findings suggest not
only that our model recapitulates early stages of colon cancer, but
also highlight the potential role of stromal HSF1 in ECM remo-
deling in human CAC.
Discussion
Long-term exposure to chronic inflammation can lead to fibrosis
and cancer. The ECM plays a crucial role in this process, however
the sequence and timing of events, and the molecular cues linking
inflammatory signals with ECM remodeling and cancer are still
not well elucidated. Here we find that the transcriptional master
regulator HSF1 is activated during early stages of inflammation in
the colon, and its activation leads to remodeling of the ECM,
supporting the development of colon cancer. Using the AOM-
DSS mouse model of CAC we analyzed ECM structure and
composition at different time points along CAC initiation and
progression in WT and Hsf1 null mice, and found that both the
structure and the composition of the ECM change at early, pre-
malignant stages. These inflammation-induced changes were
significantly inhibited by loss of HSF1, as was the consequent
progression to CAC. Establishing the relevance of our experi-
mental findings to human disease, we found high activation of
stromal HSF1 in CAC patient samples, and high conservation of
the HSF1-dependent proteomic ECM signature in human CRC.
Fig. 6 MMP7, MMP9, and LCN2 are upregulated in the stroma upon inflammation in an HSF1-dependent manner. Colons from WT and Hsf1 null mice
were excised, fixed, and stained by multiplexed immunofluorescence (MxIF) using antibodies for the depicted proteins, at different time points along the
AOM-DSS protocol. a Representative images are shown. Scale bar—50 µm. Inset scale bar—17 µm. b–g Stromal expression of each protein b–d and co-
expression with stromal HSF1 e–g were scored in 5–7 representative images from each mouse, averaged, and are presented for each mouse in the group
(see the “Methods” section for details). Results are presented as mean ± SEM, analyzed by two-way ANOVA and Bonferroni correction for multiple
comparisons. For AOM-DSS-treated mice, n= 4 or 5 WT mice (day 52 and 20 or 15, respectively) and n= 5 or 4 Hsf1 null mice (day 15 and 52, or day 20,
respectively); n= 2 mice for control; results are presented for one of two independent experiments for day 0 and 15, and were combined from two
independent experiments for days 20 and 52.
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HSF1 has been previously linked to CAC, as its activation in
cancer cells was shown to activate mTOR and increase glutami-
nolysis, thus promoting tumor growth23. Here we unravel a dif-
ferent, complementary role for HSF1, at the pre-malignant
inflammatory stage, preparing the stromal niche. Our in vitro
studies suggest that HSF1 is activated in fibroblasts, and that this
activity is required for deposition of collagen fibers. Our mouse
and human studies confirm that while HSF1 is activated in cancer
cells, it is also activated in the stroma, mainly in fibroblasts but
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including development of highly specific Cre drivers for fibroblast
and CAF subtypes48, will allow us to directly assess the inde-
pendent contribution of HSF1 in different stromal elements to
inflammation and CAC. The temporal activation pattern of
stromal HSF1 matches the course of disease, and the spatial
activation pattern matches that of ECM remodeling proteins,
suggesting that stromal HSF1 is the dominant player in the
inflammation-driven process of ECM remodeling. The proteomic
analysis was performed on bulk colons, including ECM, but also
epithelial cells, fibroblasts, and immune cells. The finding that,
within this bulk, ECM proteins are the most differentially upre-
gulated proteins between WT and Hsf1 null-treated colons fur-
ther supports the conclusion that stromal HSF1 plays a key role in
ECM remodeling in CAC.
Hsf1 null mice are highly resistant to cancer in the AOM-DSS
model. Are they also resistant to inflammation per se? Is
inflammation induced in the Hsf1 null mice? HSF1 has been
attributed both pro-inflammatory and anti-inflammatory activ-
ities. For example, it can bind to the promoter of TNFα during
proteotoxic stress and activate it49, but was also recently sug-
gested to inhibit TNFα through an alternative DNA-binding
site50. Similarly, it binds to the promoter of IL-6, but could either
activate its transcription (in response to heat-shock) or inhibit it
(in response to LPS) depending on different binding partners51,52.
It appears that different contexts (infection, heat-shock, or
mutations) result in either pro-inflammatory or anti-
inflammatory effects of HSF1. In the AOM–DSS model, differ-
ent disease metrics including disease activity, colonoscopy, and
histopathologic evaluation, as well as immune cell composition
profiling indicate that Hsf1 null mice are more moderately
affected than WT by inflammation. Moreover, our proteomic
analysis suggests that inflammation and wound healing are
among the most differentially upregulated, HSF1-dependent
pathways, suggesting that in the context of this model HSF1
promotes inflammation.
HSF1 is a transcription factor. Historically found to be acti-
vated by proteotoxic stress53, it is now well known that HSF1 is
also activated in other contexts and drives the transcription of
genes other than chaperones54,55. We have previously shown that,
in the context of cancer, HSF1 in fibroblasts drives the tran-
scription of genes involved in inflammation, ECM remodeling,
and wound healing13. Here we extend this analysis to unravel the
proteomic consequences of stromal HSF1 activation, in cancer as
well as in the preceding stage of inflammation. We propose that
HSF1 is activated in response to inflammation, driving the
transcription of genes encoding matrix proteins (FN1, LAMA1),
matrix remodeling enzymes (MMP7, MMP9), and matrix cha-
perones (SERPINH1/HSP47), inducing inflammation in a non-
cell-autonomous manner (S100A8/9, LCN2), and eventually
leading to cancer.
Our comprehensive analysis of mouse colons at different time
points along inflammation and tumor progression portrays
dynamic temporal changes in ECM structure and composition,
most of which are HSF1-dependent, and many of which precede
the appearance of tumors. This dynamic shift in matrix protein
expression is also reflected in the detection of multiple matrix
proteins that are not part of the classic colon matrisome, and are
only activated in the colon at the early stages of inflammation or
later as inflammation progresses to cancer. Such is the case for
S100A8/9, the calprotectin heterocomplex. This complex, a classic
biomarker for disease activity in IBD34, is specifically upregulated
at the premalignant stage in an HSF1-dependent manner, and is
not detected in the normal colon or in the malignant stage, nei-
ther in human nor in mice.
In humans, CAC develops in patients with IBD due to
somatic mutations and the continuous exposure to inflamma-
tion, and it is very different, both in the spectrum of genetic
alterations and in the etiology of the disease, from sporadic
colon cancer2,3. These differences were revealed by several
recent studies aimed at profiling the mutational landscape of
CAC2,3, yet we lack proteomic data to match these studies and
uncover differences in protein expression between CAC and
CRC. The vast majority of matrix proteins differentially
expressed in our AOM-DSS model is conserved in the human
colon matrisome46 and many of the proteins are upregulated in
sporadic CRC. Moreover, we find HSF1 activated in tumor-
infiltrating stroma of CAC patients and not in normal colon
fibroblasts. It is difficult to estimate the relative contribution of
inflammation per se to the proteomic changes we observe.
Recent proteomic analysis performed in mouse models of colitis,
and confirmed in IBD patients, highlighted proteomic changes
to the ECM that precede even the inflammatory symptoms9.
CAC was not monitored in these mice or patients. Whether the
changes we observe in the CAC model are associated with
inflammation, cancer, or both, and which portion of these
changes is specific to CAC and not to sporadic CRC remains to
be determined and will be the subject of future studies. Never-
theless, our findings highlight HSF1 as a key mediator of the
response to inflammation in the colon, and as such, an attractive
potential therapeutic target in IBD and CAC.
Fig. 7 Loss of Hsf1 in colon fibroblasts impairs ECM secretion. a–f Colons from day 15 AOM-DSS-treated WT or Hsf1 null mice were excised, and
fibroblasts were isolated and allowed to recover in culture for 5 days (see the “Methods” section). a, b Colon fibroblasts were induced to secrete ECM by
3–5 days incubation with MC38-conditioned media supplemented by growth factors and insulin. Representative SHG images are shown in a. The average
area of collagen covered is quantified in b for n= 6 WT and n= 5 Hsf1 null mice combined from three different experiments. Scale bar—50 µm. c Colon
fibroblasts were cultured for 5 days in the presence or absence of MC38-conditioned media, and the amount of collagen secreted by the cells was
quantified by Sirius red staining (see the “Methods” section). n= 5 WT and 4 Hsf1 null mice combined from two different experiments. d–f Representative
images of fibronectin d, MMP7 e, and MMP9 f and DAPI (nuclear) staining of colon fibroblasts cultured for 5 days in the presence of MC38-conditioned
media. For d–f n= 6 WT and n= 5 d, e or 3 f Hsf1 null mice, examined over two independent experiments. Scale bar—100 µm. g The molecular structure of
(–)-aglaroxin C (CMLD011866). h, iWT colon fibroblasts were incubated with MC38-conditioned media supplemented by growth factors and insulin in the
presence or absence of 3 nM CMLD011866 for 3–5 days, after which SHG imaging was performed. Representative images are shown in h. The average area
of collagen covered is quantified in i for n= 6 WT mice and n= 5 Hsf1 null mice, combined from three different experiments. Scale bar—50 µm. j–l Colons
from day 15 j–k or day 20 l AOM-DSS-treated WT or Hsf1 null mice were excised and decellularized. MC38 cancer cells were added and allowed to re-
cellularize the matrices (see the “Methods” section) after which SHG imaging was performed. Scale bar—50 µm. j, l Representative SHG+ IF images taken
from the mucosal side for j (upper panels) and the muscularis externa side for l. SHG is shown in red, DRAQ5 nuclear staining is shown in blue. Heatmaps
depicting the depth of invasion of cancer cells into the matrix are shown in j (bottom panels). k The average number of MC38 cells was calculated per
mouse from 3 to 7 images averaged per area, each experiment was normalized to WT and the average of three biological replicates is presented. White
arrows in l point to “holes” in the matrix where cancer cells have invaded. Results of c are presented as mean ± SEM, analyzed by two-way ANOVA and
Bonferroni correction for multiple comparisons. For b, i, and k, Results presented as mean ± SEM, analyzed by an unpaired Student’s t-test.
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Methods
Ethics statement. All clinical samples and data were collected following approval
by the Sheba Medical Center Institutional Review Board (IRB, protocol # 6141-19-
SMC and SMC-3305-16) and Ministry of Health (MOH) approval for the Israel
National Biobank for Research (MIDGAM). All animal studies were conducted in
accordance with the regulations formulated by the Institutional Animal Care and
Use Committee (IACUC; protocol # 23590116-2, 34810317-2, 03960520-2).
Human patient samples. Whole tumor sections from four CAC patients and one
normal adjacent control were retrieved and obtained from the Israel National
Biobank for Research (MIDGAM; https://www.midgam.org.il/) under IRB #6141-
19-SMC and SMC-3305-16. These samples were collected from patients who
provided informed consent for collection, storage, distribution of samples, and data
for use in future research studies.
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Mice. Hsf1 null mice and their WT littermates (BALB/c × 129SvEV, by Ivor J.
Benjamin56), were maintained under specific-pathogen-free conditions at the
Weizmann Institute’s animal facility.
Cell lines and primary cell cultures. 4T1 mouse mammary carcinoma cells were
kindly provided by Dr. Zvika Granot, Hebrew University of Jerusalem, and ori-
ginally obtained from ATCC (ATCC® CRL-2539™). MC38 mouse colon cancer cells
were kindly provided by Prof. Lea Eisenbach, Weizmann Institute of Science
(originally from NCI). Primary MEFs derived from WT or Hsf1 null mice (from
the same colony), immortalized MEFs from the same strain, 4T1 cells and MC38
cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM) (Biological
industries, 01-052-1A) supplemented with 10% fetal bovine serum (FBS) and P/S.
Primary fibroblasts from WT or Hsf1 null colons were cultured in Roswell Park
Memorial Institute 1640 (RPMI) (Biological industries, 01-100-1A) supplemented
with 10% FBS, P/S, L-glutamine, Hepes (1M), and sodium pyruvate solution
(1 mM).
Conditioned media. Cancer cell conditioned medium was produced by plating
4T1 or MC38 cancer cells to confluence in 10 cm plates, 24 h later the medium was
changed and collected 48 h later, centrifuged to remove cellular debris and stored at
−20 °C until further use. Before use the conditioned medium was diluted 1:1 with
complete medium.
Induction of collagen deposition. Immortalized or primary WT or Hsf1 null
MEFs were seeded at 1 × 105 cells/ml in 24-well plates on top of glass slides,
primary fibroblasts from WT or Hsf1 null colons were seeded on cell culture slides
(CCS-8, MatTek). 48 h later (when the cells have formed a monolayer) the medium
was replaced with collagen secretion medium57: L-ascorbic acid (cat. A8960, Sigma-
Aldrich, Rehovot, Israel) 7.5 mg/ml, h-insulin (cat. 12585-0147.5, Gibco, NY, USA)
0.25 mg/ml, m-EGF (cat. PMG804, Gibco, NY, USA), 0.25 ng/ml mixed with
conditioned medium (prepared as described above). For immortalized or primary
MEFs the medium was changed every day, for 7 or 12 days, for primary colon
fibroblasts, half of the medium was changed for 3–5 days, after which the glass
slides were removed from the plate carefully and imaged using SHG for collagen
imaging.
For HSF1 inhibition, CMLD011866 (aglaroxin C40,41) was first optimized to
determine the maximal dose at which cell viability is not compromised (500 nM).
Based on this optimization, 3 nM CMLD011866 was added daily to primary WT
colon fibroblasts for 3–5 days and SHG imaging was performed.
SHG imaging. Distal portions of the colons or slides seeded with cells for ECM
deposition assay were taken for SHG imaging using an upright Leica TCS SP8 MP
microscope, equipped with external non-descanned detectors (NDD) HyD and
acusto optical tunable filter (Leica microsystems CMS GmbH, Germany). Excita-
tion—SHG signal was excited by a 885 nm laser line of a tunable femtosecond laser
680–1080 Coherent vision II (Coherent GmbH USA). Emission signal was col-
lected using an external NDD HyD detector through a long pass filter of 440 nm.
The transmitted signal was collected using a PMT detector in transmission position
for general morphology. In addition, recellularization was imaged using excitation
of HeNe 633 laser, with emission collection at 670–760 nm.
Images were acquired using the 8 kHz resonant scanner in a format of 1024 ×
1024 (XY) through a HC PL APO 20X/0.75 CS2 objective, and the following
parameters: scan speed—8000 Hz; zoom—1.3 for colons; and 3 for in vitro ECM
deposition; line average—32; bit depth—8; FOV- X 0.416 μm, Y 0.416 μm; Z step -
0.684 μm; pixel size—416.25 nm (XY) for colons and 180.38 nm for in vitro ECM
deposition. Z stacks were acquired using the galvo stage, with 0.68 μm intervals.
ECM deposition images from primary colon fibroblasts were acquired using a
format of 1176 × 1176 (XY) with an HC FLUOTAR L 25X/0.95W VIS objective,
and the following parameters: scan speed 400 Hz; Zoom 2; Line average—3; bit
depth—8 FOV—X 0.188 μm, Y 0.188 μm; pixel size—188.45 nm.
Recellularization samples were acquired using a format of 2048 × 2048 (XY)
with an HC FLUOTAR L 25X/0.95W VIS objective, and the following parameters:
scan speed 700 Hz; zoom 1.3; line average—3; bit depth—16 FOV—X 0.166 μm, Y
0.166 μm; Z step—1 μm; pixel size—166.42 nm, Z stacks were acquired using the
galvo stage, with 1 μm intervals.
The acquired images were visualized using LASX software (Leica Application
Suite XLeica microsystems CMS GmbH).
IF imaging
MxIF. Samples from mouse colons were imaged with a LeicaSP8 confocal laser-
scanning microscope (Leica Microsystems, Mannheim, Germany), equipped with a
pulsed white-light and 405 nm lasers using a HC PL APO ×40/1.3 oil-immersion
objective and HyD SP GaAsP detectors. 0.3 μm-thick optical sections were col-
lected for each sample using the following fluorophores: DAPI (Ex. 405 nm Em.
424–457 nm); Opal 520 (Ex. 494 nm Em. 510–525 nm); Opal 570 (Ex. 568 nm Em.
575–585 nm); Opal 620 (Ex. 588 nm Em. 601–616 nm); Opal 650 (Ex. 638 nm Em.
647–664 nm); Opal 690 (Ex. 670 nm Em. 725–794 nm); and pinhole of 1 AU.
Samples were acquired using a format of 2048 × 2048 (XY), and the following
parameters: scan speed 600 Hz; zoom 1; bit depth—16; FOV—X 0.142 μm, Y
0.142 μm.
IF. Samples from primary colon fibroblasts were imaged with an inverted Leica
DMI8 wide-field (Leica Microsystems, Mannheim, Germany), Leica DFC7000GT
monochromatic camera, 20x/0.8 Air.
DSS-induced colitis and AOM-DSS-induced cancer models. DSS colitis was
induced in 8-week-old male mice by 1.5% DSS (9011-18-1, MP Biomedicals, Santa
Ana, OH) in the drinking water for 7 days followed by regular water. For AOM-
DSS, mice were injected intraperitoneally with 10 mg/kg AOM (A5486, Sigma,
Rehovot) followed by two cycles of 1.5% DSS in the drinking water, in days 7–12
and 28–33 (following Neufert et al. with modifications25). Disease progression was
monitored by weight measurement, DAI, and colonoscopies either at day 20 (for
20-day-treated mice), or days 39 and 52 (for the full protocol). Sham-treated mice
were injected with saline instead of AOM, and colonoscopies were performed as for
the treated mice.
DAI was determined as previously published58. Colonoscopy was performed
with a high‐resolution mouse video endoscopic system (Carl Storz, Tuttlingen,
Germany). Colitis colonoscopy score was determined using Murine endoscopic
index of colitis severity (MEICS), which is based on five parameters: granularity
of mucosal surface; vascular pattern; translucency of the colon mucosa; visible
fibrin; and stool consistency59. At the endpoint of the experiments mice were
sacrificed, colons were harvested and the colon weight and length was measured.
Tumor burden was quantified post-mortem by macroscopic examination of the
colons.
Each colon was cut longitudinally in two. The first half was cut again in half
and the distal part was arranged from distal (Anus) to proximal, 0.3 cm were cut
and the remaining portion was used for molecular biology methods in the
following order: SHG, RNA, mass spectrometry (1, 1.5, 2.5 cm, respectively). The
second longitudinal section was fixed in 4% paraformaldehyde over-night, and was
used for histology methods. Paraffin-embedded sections were stained at the
Weizmann histological unit using standard protocols for H&E, Masson trichrome
and Sirius red. H&E slides were scored blindly by an expert veterinary pathologist
(Dr. O. Brenner) following previously published parameters (percent of the
involved tissue, crypt damage, layers that were affected, inflammation and
regeneration)58.
FACS analysis of the innate immune profile. WT and Hsf1 null colons were
washed through a strainer with PBS, dissociated by HBSS with 5 mM EDTA and
10 mM Hepes for 20 min, incubated for 10 min on ice with Ghost-Dye-Violet 450
viability dye (TONBO), washed and resuspended with MACS buffer (PBS (calcium
and magnesium free), 0.05% BSA and 0.04% EDTA 0.5M pH 8) for 10 min on ice
with anti-mouse CD16/32 antibody. The cells were then stained with CD45-BV711,
CD11b APC-cy7, Ly6G-PE-Dazzle 594, F4/80-FITC, and Ly6C–PerCP/Cy5.5 (see
Supplementary Table 2 for details). FACS was performed using CytoFelx-S
(Beckman Coulter) and analysis was performed with FlowJo 10.1.
Chemical reagents. ((-)-Aglaroxin C (CMLD011866) was synthesized according
to published protocols40,41.
Mass spectrometry. Mass spectrometry was carried out at the Smoler Proteomic
Center at the Technion, Israel.
Proteolysis. Tissues for mass spectrometry were collected from the distal part of the
colon after a brief PBS wash, snap-frozen in liquid nitrogen and stored in −80 °C
until processing. Tissues were homogenized with an Omni-Th homogenizer in urea
buffer containing: 8 M urea, 400 mM ammonium bicarbonate, and 10 mM DTT.
Fig. 8 HSF1 and its ECM-affiliated targets are expressed in human colon cancer. a Formalin-fixed paraffin-embedded (FFPE) tumor sections from the
colons of four colitis-associated cancer (CAC) patients were stained with H&E, Sirius red (SR), Masson’s trichrome (MT), and antibodies for HSF1, and
evaluated for inflammation and HSF1 staining in cancer and stromal regions by a pathologist. A normal human colon section was stained and evaluated as
control. All sections were stained and imaged in parallel. Scale bar—150 µm. b, c Venn-diagrams representing overlap between the human colon matrisome
and the matrisome proteins detected b and differentially expressed (DE; c) in our mass spectrometry analysis. d, e Peptide abundance in normal human
colon vs. human colon cancer of matrisome proteins differentially expressed in our mass spectrometry analysis of day 0–20 d and day 52 e. Peptide
abundance values were taken from refs. 46. Statistical analysis was performed by paired t-test (two-sided).
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Homogenates were sonicated (5′, [10/10 on/off pulses], 90% energy. Sonics Vibra-
Cell) and briefly centrifuged to pellet insoluble debris. Protein amount was esti-
mated using Bradford readings. 20 μg protein from each sample were reduced with
DTT (60 °C for 30 min), modified with 40 mM iodoacetamide in 100 mM
ammonium bicarbonate (in the dark, RT, 30′) and digested in 2 M Urea, 100 mM
ammonium bicarbonate with modified trypsin (V5111, Promega, WI, USA),
overnight at 37 °C with a 1:50 enzyme-to-substrate ratio. An additional second
digestion with trypsin was done for 4 h at 37 °C with a 1:100 enzyme-to-substrate
ratio. The tryptic peptides were desalted using C18 tips (74–46, Harvard apparatus,
MA, USA) dried and re-suspended in 0.1% formic acid. The peptides were resolved
by reverse-phase chromatography on 0.075 × 300-mm fused silica capillaries (J&W
scientific) packed with Reprosil reversed phase material (Dr. Maisch GmbH,
Germany). The peptides were eluted with linear 180 min gradient of 5–28%, 15 min
gradient of 28–95%, and 25 min at 95% acetonitrile with 0.1% formic acid in water
at flow rates of 0.15 μl/min. Mass spectrometry was performed by Q Exactive plus
mass spectrometer (Thermo Fischer Scientific) in a positive mode using repetitively
full MS scan followed by high collision dissociation (HCD) of the 10 most
dominant ions selected from the first MS scan.
Analysis. The mass spectrometry data from all the biological repeats was analyzed
using the MaxQuant software 1.5.2.860 vs. the Mus-Musculus portion of the Uni-
prot database, with 1% FDR. The data was quantified by label-free analysis using
the same software, based on extracted ion currents (XICs) of peptides enabling
quantitation from each LC/MS run for each peptide identified in any of experi-
ments. Statistical analysis of the identification and quantification of results was
done using Perseus 1.5.2.4 software61. Day 52 samples ran separately from day 0
and day 20 samples, and were therefore also analyzed separately. LFQ intensities
were filtered by minimum number of Razor+ unique peptides ≤ 2. LFQ intensities
were Log2 transformed and known contaminants were removed. Only the first
majority protein ID was used for annotation, zero values were replaced with 15.
Proteins for which there was no agreement of expression between the two samples
of day 0 were removed from the analysis. For the day 0–20 data set, 3830 proteins
passed filtration. Two-way ANOVA+multiple testing correction test (step-up)
was applied to detect differentially expressed proteins between the Hsf1 null and
WT samples. A cutoff value of fold change >1.5 and FDR= < 0.1. was used and
revealed 265 proteins as differentially expressed. For Day 52, 4234 proteins passed
the filters above. Unpaired Students’ t-test (two-sided) was applied to detect dif-
ferentially expressed proteins, resulting in 313 proteins with FDR < 0.1.
Partitional clustering was applied on log2 transformed and standardized
expression values, using the k-means algorithm (Euclidian method) for the day
0–20 data. Pathway analysis was done using the gProfiler web tool
(e101_eg48_p14_baf17f0)62.
Matrisome analysis. To create a list of all the matrisome proteins detected in
our data we first compared our list of all detected proteins, and our lists of dif-
ferentially expressed (DE) proteins, with comprehensive matrisome lists available
through the Matrisome project for human and mouse26. Next we compared
our lists of detected and DE matrisome proteins with the mouse colon matri-
some28, and with the human colon matrisome (compiled from normal colon,
primary CRC and metastatic colon CRC46). Finally, we compared peptide abun-
dance of our DE matrisome proteins in normal human CRC vs primary and
metastatic CRC.
Immunohistochemistry of human tissues. Colons dissected as described above
were fixed in 4% paraformaldehyde (PFA), processed and embedded in paraffin
blocks, cut into 4–5 μm sections and immunostained as follows: formalin-fixed,
paraffin-embedded (FFPE) sections were deparaffinized, treated with 0.3% H2O2
and antigen retrieval was performed by microwave (2 min full power, 1000W, then
10 min at 30% of full power, and then cooling at RT for 10 min) with citrate acid
buffer (pH 6.0). Slides were blocked with 10% normal horse serum, and anti-HSF1
antibodies were used (see Supplementary Table 2 for details). Visualization was
achieved with 3,30-diaminobenzidine (DAB) as a chromogen (#SK4100, Vector
Labs kit, CA, USA). Counterstaining was performed with Mayer-hematoxylin
(MHS-16, Sigma-Aldrich, Rehovot, Israel). Images were taken with a Nikon Eclipse
Ci microscope and Pannoramic Scan II scanner, ×20/0.8 objective (3DHISTECH,
The Digital Pathology Company, Budapest, Hungary).
Immunofluorescent staining of mouse and human tissues. FFPE sections from
mouse colons were deparaffinized, and incubated in 10% neutral buffered formalin
(NBF prepared by 1:25 dilution of 37% formaldehyde solution in PBS) for 20 min
in room temperature, washed (with PBS) and then antigen retrieval was performed
by microwave (2 min full power, 1000W, then 10 min at 30% of full power) with
citrate buffer (pH 6.0). Slides were blocked with 10% BSA+ 0.05% Tween20 and
the antibodies listed in the table below were diluted in 2% BSA in 0.05% PBST and
used in a multiplexed manner with the OPAL reagents, each one O.N. at 4 °C. The
OPAL is a stepwise workflow that involves tyramide signal amplification. This
enables simultaneous detection of multiple antigens on a single section by pro-
ducing a fluorescent signal that allows multiplexed immunohistochemistry, ima-
ging, and quantitation (Opal Reagent pack and amplification diluent, Akoya
Bioscience). Briefly, following over-night incubation with primary antibodies, slides
were washed with 0.05% PBST, incubated with secondary antibodies conjugated to
HRP for 10 min, washed again and incubated with OPAL reagents for 10 min.
Slides were then washed and microwaved (as describe above), washed, stained with
the next primary antibody or with DAPI in the end of the cycle and mounted. We
used the following staining sequences: (1) αSMA, HSF1, MMP9, LCN2, MMP7; (2)
SERPINH1, FN1. S100A8 was stained separately. Each antibody (see Supplemen-
tary Table 2 for details) was validated and optimized separately, and then multi-
plexed immunofluorescence (MxIF) was optimized to confirm that signals were not
lost or changed due to the multistep protocol. The slides of sequence (1) were
imaged with a DMi8 Leica confocal laser-scanning microscope, using a HC PL
APO ×40/1.3 oil-immersion objective HyD SP GaAsP detectors. The slides of
sequence (2) and of S100A8 were imaged with the Pannoramic Scan II scanner,
×20/0.8 objective (3DHISTECH, The Digital Pathology Company, Budapest,
Hungary).
Isolation of primary colon fibroblasts. Primary colon fibroblasts were produced
from WT or Hsf1 null mice on day 15 of the AOM-DSS protocol using a standard
protocol63. Briefly, mice were euthanized and their colons were removed and washed
with cold PBS. The colons were opened and epithelial cells were denuded by three
repeated washes of 15min at 37 °C, 250 rpm in a tilted shaker-incubator, in HBSS
(Cat. H6648, Sigma-Aldrich, Rehovot, Israel) with 5mM EDTA and P/S, after which
the tissue was washed again with cold PBS and put in complete RPMI 1640 medium
(described above) with 3.5mg/ml Collagenase D (Cat. 11088866001, Merck, Reho-
vot, Israel) and 10 U of Dispase II (Cat.D4693, Sigma-Aldrich, Rehovot, Israel) for
1 h in 37 °C at 250 rpm in a flat shaker-incubator. Tissues were then spun down at
300×g for 5 min and reconstituted with 5ml complete RPMI 1640 and seeded on
60mm plates coated with collagen I (Cat. C3867, Sigma-Aldrich, Rehovot, Israel).
Cells were incubated for 5 days before seeding for experiments.
Total collagen detection in vitro. WT and Hsf1 null primary colon fibroblasts
were seeded at 2 × 105 cells/ml in 96-well plates. 24 h later (when the cells have
formed a monolayer) the medium was replaced with either the same medium (as
control) or with MC38 condition medium (prepared as described above) supple-
mented with collagen secretion medium57 (L-ascorbic acid (cat. A8960, Sigma-
Aldrich, Rehovot, Israel) 7.5 mg/ml; h-insulin (cat. 12585-0147.5, Gibco, NY, USA)
0.25 mg/ml; m-EGF (cat. PMG804, Gibco, NY, USA) 0.25 ng/ml. Half of the
medium was changed every day, for 5 days, after which cell lysates were removed
with acetic acid 0.5 M, and Sirius Red total collagen detection assay kit (cat. 9062,
Chondrex, WA, USA) was used according to manufactures’ protocol to measure
fibrillar collagen content.
Immunofluorescent staining of primary colon fibroblasts. Primary colon
fibroblast were seeded at 1 × 105 cells/ml in 24-well plates on top of glass slides.
48 h later (when the cells have formed a monolayer) the medium was replaced with
collagen secretion medium as described above, for 5 days, after which the cells were
fixed with 4% paraformaldehyde (PFA) for 10 min, washed and permeabilized
using 0.1% Triton X-100 for 10 min. Samples were blocked with 1% BSA in 0.05%
PBST for 1 h, incubated with primary antibodies (FN1, MMP7, MMP9) overnight,
and with AF647 secondary antibodies for 1 h. Samples were imaged as
described above.
Decellularization and recellularization of colon tissue. Colon tissue decellular-
ization was performed according to a protocol adapted from Silva et al.45. Briefly,
~10 mm × 5mm of colon tissue with agitation at 165 rpm (shaker-incubator with
orbit diameter of 20 mm) and at 25 °C, unless specified otherwise. Following
thawing, colon tissue was incubated for 18 h in a hypotonic buffer (10 mM Tris
HCl/0.1% EDTA, pH 7.8) and washed three times in PBS (1 h per wash). Samples
were then immersed in detergent solution (0.2% sodium dodecyl sulfate (SDS)/10
mM Tris–HCl, pH 7.8) for 24 h, washed three times (20 min per wash) with the
hypotonic wash buffer (10 mM Tris–HCl, pH 7.8) and incubated for 3 h, at 37 °C,
in DNAse solution (50 U/mL DNAse I (Cat. LS00200, Worthington, NJ, USA)/10
mM Tris–HCl, pH 7.8). Three final washes in PBS were performed (20 min per
wash) to remove residual detergent and DNAse. Decellularized matrices were kept
under sterile conditions, at 4 °C in PBS supplemented with 1% P/S until use.
Recellulriztion was performed as following: The decellularized tissue was incubated
in DMEM for 1 h at 37 °C, after which it was gently deployed at a fixed orientation
(under microscopy guidance) on a Petri dish (60 mm) and 0.5 × 106 MC38 cells
were seeded through a strainer (40 μm) in 1 ml of medium. After 40 or 72 h for day
15 or 20, respectively, the colon tissues were fixed with 4% PFA for 10 min, washed
gently with PBSx1, stained with DRAQ5 for 10 min and washed again. The samples
were imaged as described above.
RNA sequencing. Tissues for RNA-seq were collected from the distal part of the
colon after a brief PBS wash, snap-52frozen in liquid nitrogen and stored in −80 °C
until processing. Tissues were homogenized using Fisherbrand bead mill and RNA
was extracted using RNeasy fibrous tissue mini kit according to manufactures
protocol (Cat. 74704, Qiagen, MD, USA). RNA libraries were prepared using the
SENSE mRNA-seq library prep kit (Cat. 001, Lexogen, Vienna, Austria). Libraries
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were sequenced using the NovaSeq 6000 machine (Illumina, CA, USA) and reads
were aligned to the mouse reference genome (mm10) using STAR v2.4.2a64 with
default parameters. Counts were normalized using Deseq265. RNA sequencing
results are detailed in Supplementary Data 5. Hierarchical clustering was performed
using Euclidian distance on differentially expressed genes which were filtered with
the following parameters: baseMean >5, padj < 0.05 and |logfoldchange | >1. Ana-
lysis was performed by R software v.3.6. Pathway analysis was performed using the
g-profiler web tool62. Significant pathways were determined if p < 0.05 (for details
see Supplementary Data 7). Comparison of the RNA-seq data to ECM proteins was
done using the mouse matrisome data base26 (for more information see Supple-
mentary Data 9).
Image analysis
MxIF. MxIF images from the distal half of the colon were analyzed using Fiji image
processing platform66. Analysis of MxIF staining for HSF1, SMA, LCN2, MMP7,
MMP9 was performed as following: five slices—were Z projected (Average) and
linear spectral unmixing was performed. Manual scoring was then performed in a
blinded manner by three independent experts for epithelial cells and stromal cells
separately (excluding the submucosa and tunica muscularis), considering the
number of positive cells, co-expression between markers, and the total amount of
epithelial cells or stromal cells in the image. These scores were averaged and are
presented. For S100A8, FN1, and SERPINH1 staining regions of interest (ROIs)
were manually depicted using QuPath67 (0.2.0-m8) to include all intact tissue areas
in the vertical orientation and exclude regions of tunica muscularis (due to its
tendency to display nonspecific staining). Following background subtraction using
a rolling ball all the channels were automatically thresholded (Triangle method).
For S100A8 quantification, Threholded areas were normalized to ROI. For FN1
and SERPINH1 changes in localization were evaluated manually and indepen-
dently by two blinded experts and representative images were selected accordingly.
SHG
Collagen covered area. Collagen covered area was analyzed using LAS X 3D
Analysis, starting with the following pre-filter processing: (1) enhance white detail
(size 2); (2) stretch the histogram; and (3) noise removal median (size 1). Next, we
used a fixed threshold, which was set manually, to detect the collagen matrix.
Spatial analysis of distances between crypts. We started with Max projection of
the 3D stack, and trained Ilastik (1.3.3b2)68 AutoContext Pixel Classifier to classify
pixels into crypts vs. collagen fibers, on selected images. A dedicated Fiji macro66
applied this classifier to each image, and segmented the individual crypts using
hysteresis thresholding from 3D ImageJ Suite plugin69. Holes in the crypt objects
were filled and objects smaller than 300 μm2 were discarded. For each image we
measured the number of crypts completely included in the image, and the average
size of those crypts.
To quantify fibrosis we calculated the border-to-border shortest distances
between neighboring crypts using 3D image-J suite plugin69. We further looked at
the following measures: the border-to-border distance to the nearest crypt, and the
number of neighboring crypts within 20 μm from the crypt border. Images of
segmented crypts color-coded by these measurements were created using
MorphoLibJ plugin70.
The values for crypts on the border of the image were not used in the statistics,
but those crypts were taken into account as neighbors of in-image crypts. This
automatic process segmented correctly most of the crypts. Further manual
correction was done to fix for segmentation errors. All the measurements were
recalculated based on the corrected segments. The macro allows for this by saving
crypts contours in a file, and by providing an update mode to calculate the
measurements from a segments file. The macro is available on Github [https://
github.com/WIS-MICC-CellObservatory/Crypts_SpatialOrganization/].
Recellularization of MC38 cells on WT or Hsf1 null colons. The number of
MC38 cells growing on WT or Hsf1 null colons was calculated using Imaris (9.6.0,
Bitplane) “surface” module to segment the nuclei. Segmentation was done using
absolute intensities of the DAPI channel, default smoothing settings, an automatic
threshold, and splitting touching objects according to a seed point diameter of 7
μm. A fixed quality value for selecting seed points was selected manually and
applied for all the images. Small objects were discarded using a fixed threshold.
Color-coded maps of depth were created by coloring each nucleus by its z-
position value.
It should be noted that WT colon samples are more fibrotic, and are therefore
thicker than Hsf1 null samples. Figure 7j top panel shows a merged image of SHG
channel (averaged section of 5 μm) and nuclei channel (averaged across all section).
Collagen contraction assay. For the gel contraction assay 0.5 × 106 primary colon
fibroblast were seeded in 100 μl volume of Matrigel solution containing 0.1%
serum-FBS, 0.2% 5x RPMI buffer (52 mg RPMI, 20 mg NaCHO3, 10 μl HEPES 1
M, and 0.9 ml DDW), 0.2% Matrigel (Corning, #354230), 0.4% Collagen type I
(Corning, #354230), and 0.1% PBS. The mixed collagen-cells were plated in 96-well
plates and incubated for 15 min at 37 °C after which ‘control medium’ (RPMI
1640) or 0.75% ‘conditioned medium’ (as described above) mixed with regular
medium was added. Plates were scanned 3 days later and the area that covered with
gel was measured.
Statistical analysis. Statistical analysis and visualization were performed using R
(Version 3.6.0, R Foundation for Statistical Computing Vienna, Austria) and Prism
8.2.0. Statistical significance tests were performed as described in each figure
legend. Unless stated otherwise all ANOVA tests were significant with p value <
0.05. p values > 0.05 were defined as not significant and are not presented in the
graphs. We excluded 1 WT mouse from crypt size (11,000 μm²) quantification
presented in Fig. 3, since it was an outlier (statistically significantly different from
group average).
Data availability
The proteomics data generated and analyzed in this study has been deposited in the
Proteomics Identification Database (PRIDE) number PXD022207. RNA-sequencing data
has been deposited in Gene Expression Omnibus (GEO) number GSE158276. The
remaining data are available within the Article, Supplementary Information or available
from the authors upon request.
Code availability
Script and auxiliary data needed to reconstruct “spatial analysis of distances between
crypts” analysis files are available from GitHub [https://github.com/WIS-MICC-
CellObservatory/Crypts_SpatialOrganization/] and from Zenodo [https://doi.org/
10.5281/zenodo.4172577].
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